TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Vistin Pharma ASA
Closing information (x1000 EUR)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
36,222
|
38,734
|
27,329 |
| Financial expenses |
1,229
|
2,751
|
899 |
| Earnings before taxes |
6,792
|
5,206
|
-571 |
| Total assets |
32,496
|
35,887
|
38,685 |
| Current assets |
12,087
|
15,015
|
15,122 |
| Current liabilities |
5,400
|
6,181
|
11,190 |
| Equity capital |
26,129
|
28,715
|
25,960 |
| - share capital |
3,743
|
3,945
|
4,213 |
| Employees (average) | 0 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
80.4%
|
80.0%
|
67.1% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
18.8%
|
13.4%
|
-2.1% |
| Return on assets (ROA) |
24.7%
|
22.2%
|
0.8% |
| Current ratio |
223.8%
|
242.9%
|
135.1% |
| Return on equity (ROE) |
26.0%
|
18.1%
|
-2.2% |
| Change turnover |
-532
|
13,141
|
1,127 |
| Change turnover % |
-1%
|
51%
|
4% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.